Review Article

Targeting Apelinergic System in Cardiometabolic Disease

Author(s): Rui Guo, Olivia Rogers and Sreejayan Nair*

Volume 18, Issue 15, 2017

Page: [1785 - 1791] Pages: 7

DOI: 10.2174/1389450117666160613105152

Price: $65

Abstract

Background: Global burden of cardiometabolic disease warrants development of newer treatment strategies. Apelin is ubiquitously expressed endogenous peptide which is a ligand for the apelinergic (APJ) receptor. Apelin/APJ receptors regulate a variety of biological functions and have been implicated in cardiovascular and metabolic homeostasis. Consequently, the apelinergic pathway represents an attractive target to treat conditions associated with cardiometabolic syndrome.

Objective: This review highlights the important regulatory role played by apelin in energy metabolism and cardiovascular function, and potential avenues that could be harnessed for therapeutic benefit.

Conclusion: Apelin/APJ system is a druggable target to treat or prevent a variety of cardiometabolic diseases.

Keywords: Apelin, apelinergic receptor, energy metabolism, cardiovascular disease, diabetes, metabolic syndrome, polymorphism.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy